For the quarter ended September 2025, AbbVie (ABBV) reported revenue of $15.78 billion, up 9.1% over the same period last year. EPS came in at $1.86, compared to $3.00 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $15.59 billion, representing a surprise of +1.2%. The company delivered an EPS surprise of +5.08%, with the consensus EPS estimate being $1.77.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Oncology- Elahere- Total: $170 million compared to the $199.05 million average estimate based on six analysts. The reported number represents a change of +22.3% year over year.
- Net Revenue- Creon- US: $368 million compared to the $350.08 million average estimate based on five analysts. The reported number represents a change of +8.9% year over year.
- Net Revenue- Rinvoq- International: $625 million versus the five-analyst average estimate of $606.08 million. The reported number represents a year-over-year change of +40.8%.
- Net Revenue- Humira- US: $619 million versus the five-analyst average estimate of $764.72 million. The reported number represents a year-over-year change of -64.9%.
- Net Revenue- Neuroscience- Total: $2.84 billion versus $2.74 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +20.2% change.
- Net Revenue- Vraylar- Total: $934 million compared to the $946.65 million average estimate based on six analysts. The reported number represents a change of +6.7% year over year.
- Net Revenue- Immunology- Total: $7.89 billion versus the six-analyst average estimate of $7.88 billion. The reported number represents a year-over-year change of +11.9%.
- Net Revenue- Rinvoq- Total: $2.18 billion versus the six-analyst average estimate of $2.16 billion. The reported number represents a year-over-year change of +35.3%.
- Net Revenue- Botox Therapeutic- Total: $985 million compared to the $922.4 million average estimate based on six analysts. The reported number represents a change of +16.2% year over year.
- Net Revenue- Juvederm Collection- Total: $253 million versus the six-analyst average estimate of $257.9 million. The reported number represents a year-over-year change of -1.9%.
- Net Revenue- Botox Cosmetic- Total: $637 million versus $686.58 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -5.1% change.
- Net Revenue- Imbruvica: $706 million compared to the $708.25 million average estimate based on six analysts. The reported number represents a change of -14.7% year over year.
View all Key Company Metrics for AbbVie here>>>
Shares of AbbVie have returned -3.5% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
